mRNA-1273 and Ad26.COV2.S vaccines protect against B.1.621 variant of SARS-CoV-2

Here, we evaluated in mice and hamsters the efficacy of a pre-clinical version of the Moderna mRNA vaccine (mRNA-1273) and the Johnson and Johnson recombinant adenoviral-vectored vaccine (Ad26.COV2.S) against the B.1.621 (Mu) variant of SARS-CoV-2, which contains spike mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, and D950N.

本研究在小鼠与仓鼠模型中，评估了莫德纳（Moderna）mRNA疫苗临床前版本mRNA-1273，以及强生（Johnson & Johnson）重组腺病毒载体疫苗Ad26.COV2.S，针对携带刺突蛋白（spike）突变T95I、Y144S、Y145N、R346K、E484K、N501Y、D614G、P681H及D950N的SARS-CoV-2 B.1.621（Mu）变异株的保护效力。